Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bluebird Bio
Biotech
ASH: Editas shares data for mid-stage sickle cell disease asset
After two landmark FDA approvals in sickle cell disease, Editas is sharing data for its gene-edited candidate designed to tackle the same condition.
Gabrielle Masson
Dec 11, 2023 2:33pm
Bluebird closer to lovo-cel approval after FDA smooths path
Aug 16, 2023 9:59am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
Bluebird's sickle cell trial in under-18s back after year hold
Dec 19, 2022 10:55am
2 biotechs pen licensing pact for cell therapy cancer platform
Oct 27, 2022 11:00am
Where are they now? Tracking down 2012's Fierce 15
Aug 29, 2022 3:00am